Accelerating Product Innovation and Availability

Improving how prevention is delivered

Developing a rich pipeline of options for HIV prevention is essential and must be guided by community priorities that define what products are needed and supported through R&D.

Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.

AVAC’s work supports:

The Latest on Accelerating Product Innovation

Event

Update on Injectable Lenacapavir for PrEP

SAVE THE DATE: Join AVAC, Gilead and partners for a discussion of and comprehensive presentation on lenacapavir for PrEP data from the PURPOSE I and II trials, along with an update on where we are with global access and regulatory submissions.

More details, including registration, to come.

Report

An Advocate’s Guide to Research in Pregnant and Lactating Populations

A resource that provides background on the need for research in pregnant and lactating populations and how advocates can advance inclusion.